Suppr超能文献

骨髓抽吸浓缩物与富血小板血浆或透明质酸治疗膝骨关节炎的比较。

Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.

机构信息

Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.

Department for Orthopedic Surgery and Traumatology, Clinical Center of Vojvodina, Hajduk Veljkova 1-9, 21000 Novi Sad, Serbia.

出版信息

Medicina (Kaunas). 2021 Nov 2;57(11):1193. doi: 10.3390/medicina57111193.

Abstract

In the last decade, regenerative therapies have become one of the leading disease modifying options for treatment of knee osteoarthritis (OA). Still, there is a lack of trials with a direct comparison of different biological treatments. Our aim was to directly compare clinical outcomes of knee injections of Bone Marrow Aspirate Concentrate (BMAC), Platelet-rich Plasma (PRP), or Hyaluronic acid (HA) in the OA treatment. Patients with knee pain and osteoarthritis KL grade II to IV were randomized to receive a BMAC, PRP, and HA injection in the knee. VAS, WOMAC, KOOS, and IKDC scores were used to establish baseline values at 1, 3, 6, 9, and 12 months. All side effects were reported. A total of 175 patients with a knee osteoarthritis KL grade II-IV were randomized; 111 were treated with BMAC injection, 30 with HA injection, and 34 patients with PRP injection. There were no differences between these groups when considering KL grade, BMI, age, or gender. There were no serious side effects. The mean VAS scores after 3, 7, 14, and 21 days showed significant differences between groups with a drop of VAS in all groups but with a difference in the BMAC group in comparison to other groups ( < 0.001). There were high statistically significant differences between baseline scores and those after 12 months ( < 0.001) in WOMAC, KOOS, KOOS pain, and IKDC scores, and in addition, there were differences between these scores in the BMAC group in comparison with other groups, except for the PRP group in WOMAC and the partial IKDC score. There were no differences between the HA and PRP groups, although PRP showed a higher level of clinical improvement. Bone marrow aspirate concentrate, Leukocyte rich Platelet Rich Plasma, and Hyaluronic acid injections are safe therapeutic options for knee OA and provide positive clinical outcomes after 12 months in comparison with findings preceding the intervention. BMAC could be better in terms of clinical improvements in the treatment of knee OA than PRP and HA up to 12 months. PRP provides better outcomes than HA during the observation period, but these results are not statistically significant. More randomized controlled trials and high quality comparative studies are needed for direct correlative conclusions.

摘要

在过去的十年中,再生疗法已成为治疗膝骨关节炎 (OA) 的主要疾病修饰选择之一。尽管如此,仍然缺乏不同生物治疗方法的直接比较试验。我们的目的是直接比较骨髓抽吸浓缩物 (BMAC)、富含血小板的血浆 (PRP) 或透明质酸 (HA) 膝关节注射治疗 OA 的临床结果。膝关节疼痛和骨关节炎 KL 分级 II 至 IV 的患者被随机分为接受 BMAC、PRP 和 HA 膝关节注射。使用 VAS、WOMAC、KOOS 和 IKDC 评分在 1、3、6、9 和 12 个月时建立基线值。报告了所有副作用。共有 175 名 KL 分级 II-IV 的膝关节骨关节炎患者被随机分组;111 名患者接受 BMAC 注射治疗,30 名患者接受 HA 注射治疗,34 名患者接受 PRP 注射治疗。考虑 KL 分级、BMI、年龄或性别时,这些组之间没有差异。没有严重的副作用。3、7、14 和 21 天后的平均 VAS 评分显示组间存在显著差异,所有组的 VAS 评分均下降,但 BMAC 组与其他组相比差异有统计学意义 ( < 0.001)。WOMAC、KOOS、KOOS 疼痛和 IKDC 评分的基线评分与 12 个月后的评分之间存在高度统计学差异 ( < 0.001),此外,除了 PRP 组在 WOMAC 和部分 IKDC 评分方面,与其他组相比,BMAC 组的这些评分之间也存在差异。HA 和 PRP 组之间没有差异,尽管 PRP 显示出更高的临床改善水平。骨髓抽吸浓缩物、富含白细胞的富血小板血浆和透明质酸注射是膝关节 OA 的安全治疗选择,与干预前的发现相比,在 12 个月后提供了积极的临床结果。在治疗膝关节 OA 方面,BMAC 在临床改善方面可能优于 PRP 和 HA,长达 12 个月。在观察期间,PRP 提供的结果优于 HA,但这些结果没有统计学意义。需要更多的随机对照试验和高质量的比较研究来得出直接相关的结论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d6f/8623697/de9cd32e15f4/medicina-57-01193-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验